AbbVie Inc. (NYSE:ABBV) shares are trading lower on Monday.

The U.S. drug maker shared topline results from a Phase 1 study of ABBV-295, a long-acting amylin analog aimed at treating obesity.

In March 2025, AbbVie and Gubra A/S announced a license agreement to develop GUB014295 (ABBV-295).

The stock’s performance comes as the broader market is experiencing some pressure, with the S&P 500 down 0.9% and the Healthcare sector losing 0.4%.

AbbVie’s Obesity Data

In the Phase 1 study, AbbVie reported that ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight, with mean percentage changes ranging from -7.75% to -9.79% at week 12.

The treatment was generally well tolerated, with mild gastrointestinal disorders being the most commonly reported adverse events.

The study involved various dosing regimens, with different doses tested between 2 mg and ...